Carmot Therapeutics was founded by Kian Chow in 2008. According to Bloomberg, Carmot Therapeutics announced its plans to go public in November 2023. However, in December 2023, Roche bought Carmot Therapeutics for $3.1 billion due to the high demand for obesity pharmaceuticals.

Carmot Therapeutics is a biotechnology company that helps people with metabolic diseases such as diabetes. Per Forge data, Carmot Therapeutics has raised a total of $384.8 million in 8 funding rounds. Their latest funding was raised on May 25, 2023, from a Series E round. Key investors include Amgen Ventures, Deep Track Capital, Horizen Ventures, and The Column Group.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Carmot Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Carmot Therapeutics

Forge green plus iconForge green minus icon

What is Carmot Therapeutics's IPO price?

The IPO price for Carmot Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Carmot Therapeutics?

Carmot Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Carmot Therapeutics shares pre-IPO?

If you own Carmot Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Carmot Therapeutics a publicly traded company?

Carmot Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Carmot Therapeutics's funding to date?

Carmot Therapeutics has raised $372.31MM to date.
Forge green plus iconForge green minus icon

When was Carmot Therapeutics founded?

Carmot Therapeutics was founded in 2008.

Who are Carmot Therapeutics's major investors?

Horizon Ventures
Janus Henderson Investors
Amgen Ventures
Deep Track Capital
5AM Ventures

Carmot Therapeutics funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation

Series E

$150MM raised $XXX.XX $XXX.XX

Series D and D-1

$160.67MM raised $XXX.XX $XXX.XX

Series C

$46.88MM raised $XXX.XX $XXX.XX

Series B

$12.59MM raised $XXX.XX $XXX.XX

Series A

$2.16MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.